Acurx Pharmaceuticals (ACXP)
(Delayed Data from NSDQ)
$2.02 USD
0.00 (0.05%)
Updated Apr 26, 2024 11:40 AM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Acurx Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -14.58 | -12.09 | -12.75 | -4.60 | -5.93 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | 1.14 | 1.25 | 0.14 | -0.80 | 1.05 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.64 | 3.30 | 7.59 | 2.05 | 0.90 |
Net Cash From Operating Activities | -9.80 | -7.54 | -5.01 | -3.35 | -3.99 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 8.16 | 3.70 | 14.80 | 4.04 | 4.46 |
Net Cash from Financing Activities | 8.16 | 3.70 | 14.80 | 4.04 | 4.46 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -1.64 | -3.85 | 9.78 | 0.69 | 0.47 |
Cash at Beginning of Period | 9.11 | 12.96 | 3.18 | 2.48 | 2.01 |
Cash at End of Period | 7.47 | 9.11 | 12.96 | 3.18 | 2.48 |
Diluted Net EPS | -1.15 | -1.12 | -1.49 | -0.74 | NA |
Fiscal Year End for Acurx Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -14.58 | -9.46 | -6.35 | -2.90 |
Depreciation/Amortization & Depletion | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | NA | 1.14 | 1.32 | 1.13 | 0.07 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 3.64 | 2.54 | 1.71 | 0.90 |
Net Cash From Operating Activities | NA | -9.80 | -5.60 | -3.51 | -1.93 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 8.16 | 3.54 | 3.54 | 0.00 |
Net Cash from Financing Activities | NA | 8.16 | 3.54 | 3.54 | 0.00 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -1.64 | -2.06 | 0.03 | -1.93 |
Cash at Beginning of Period | NA | 9.11 | 9.11 | 9.11 | 9.11 |
Cash at End of Period | NA | 7.47 | 7.05 | 9.15 | 7.18 |
Diluted Net EPS | NA | -0.38 | -0.24 | -0.28 | -0.25 |